underwriting compensation.The underwriters have an option to purchase a maximum of 600,000 additional shares of common stock from us at the initial public offering price less the underwriting discount.Certain of our existing stockholders and their affiliated entities, including Aisling Capital and affiliates of Goldman, Sachs & Co., have indicated an interest to
companies.5Table of ContentsThe OfferingCommon stock offered by us4,000,000 sharesCommon stock to be outstanding after this offering18,021,604 sharesOption to purchase additional sharesThe underwriters have a 30-day option to purchase a maximum of 600,000 additional shares of common stock.Use of proceedsWe intend to use the net proceeds from this offering to commercialize our T2Dx and T2Candida product candidates if they receive marketing authorization from the FDA, to fund development of our other
occur upon the closing of this offering; and•no exercise by the underwriters of their option to purchase additional shares of our common stock.Certain of our existing stockholders and their affiliated entities, including Aisling Capital and affiliates of Goldman, Sachs & Co., have indicated an interest to
necessarily indicative of the results that may be expected for the year ending December 31, 2014 or any other interim periods or any future year or period.Period fromApril 27,2006(Inception) toMarch 31,2014Year EndedDecember 31,Three Months EndedMarch 31,2012201320132014(in thousands, except share andper share data)Statement of Operations Data:Research and grant revenue$19$266$—$—$3,085Operating expenses:Research and development11,72714,9363,5615,06559,388Selling, general and administrative2,9455,0221,0391,84222,552​​​​​​​​​​​​​​​​​Total operating expenses14,67219,9584,6006,90781,940​​​​​​​​​​​​​​​​​Interest expense, net(154)(403)(105)(86)(937)Other income (expense), net352(515)12573611​​​​​​​​​​​​​​​​​Net loss(14,455)(20,610)(4,580)(6,920)(79,181)​​​​​​​​​​​​​​​​​Accretion of redeemable convertible preferred stock to redemption value(4,412)(6,908)(1,176)(1,906)(21,307)​​​​​​​​​​​​​​​​​Net loss applicable to common stockholders$(18,867)$(27,518)$(5,756)$(8,826)$(100,488)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Net loss per share applicable to common stockholders – basic and diluted(1)$(13.86)$(19.72)$(4.17)$(6.25)$(99.66)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Weighted-average number of common shares used in computing net loss per share applicable to common stockholders – basic and diluted(1)1,361,6161,395,5621,380,3031,411,9611,008,304​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​8Table of ContentsPeriod fromApril 27,2006(Inception) toMarch 31,2014Year EndedDecember 31,Three Months EndedMarch 31,2012201320132014(in thousands, except share andper share data)Pro forma net loss per share applicable to common stockholders – basic and diluted (unaudited)(1)$(1.53)$(0.50)$(13.33)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Pro forma weighted-average number of common shares used in computing net loss per share applicable to common stockholders – basic and diluted
underwriting discount and estimated offering expenses payable by us.As of March 31, 2014ActualPro formaPro forma asadjusted(in thousands)Balance Sheet Data:Cash and cash equivalents$23,698$30,323$87,323Total assets25,83232,45789,457Current liabilities5,2013,7173,717Notes payable, net of current portion2,85511,00011,000Warrants to purchase redeemable securities1,152——Total stockholders' (deficit) equity(98,130)17,70574,705Each $1.00 increase (decrease) in the assumed initial public offering price of $16.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
However, we may need to raise substantial additional capital to:•expand our product candidate offerings;•expand our sales and marketing infrastructure;•increase our manufacturing capacity;•fund our operations; and•continue our research and development activities.Our
future funding requirements will depend on many factors, including:•our ability to obtain marketing authorization from the FDA or clearance from the FDA to market our product candidates;•market acceptance of our product candidates, if cleared;•the cost and timing of establishing sales, marketing and distribution capabilities;•the cost of our research and development activities;•the ability of healthcare providers to obtain coverage and adequate reimbursement by third-party payors for procedures
Any of these factors could harm our operating results.Our future success is dependent upon our ability to create and expand a customer base for our product candidates in large hospitals.We anticipate marketing our initial product candidates, if they receive marketing authorization from the FDA, to the approximately 450
If we fail to compete effectively, our business and operating results will suffer.If our product candidates receive marketing authorization or are cleared or approved, we will compete with commercial diagnostics
without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future.We may not be able to develop new product candidates or enhance the capabilities of our systems to keep pace with our industry's rapidly changing technology and customer
requirements, which could have a material adverse impact on our revenue, results of operations and business.Our industry is characterized by rapid technological changes, frequent new product introductions and enhancements and evolving
damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.We currently develop our diagnostic product candidates exclusively in a facility in Lexington, Massachusetts and manufacture and test
such a transaction;•unanticipated liabilities related to acquired companies;•difficulties integrating acquired personnel, technologies and operations into our existing business;19Table of Contents•diversion of management time and focus from operating our business to acquisition integration challenges;•increases in our expenses and reductions in our cash available for operations and other uses;•possible write-offs or impairment charges relating to acquired businesses; and•inability to develop a sales force for any additional product candidates.Foreign
clinical data is stored are attacked by a physical or electronic break-in, computer virus or other malicious human action, our confidential information could be stolen or destroyed.Risks Related to Government Regulation and Diagnostic Product ReimbursementApproval and clearance by the FDA and foreign regulatory authorities for our diagnostic tests will take significant time and require significant research, development and
of our diagnostic product candidates outside the United States are subject to foreign regulatory requirements governing clinical studies, vigilance reporting, marketing approval,
management from operating our business and may harm our reputation and financial results.We may rely on third parties to conduct future studies of our product candidates that may be required by the FDA or other regulatory authorities, and those third parties may
The market price for our common stock may be influenced by many factors, including:•actual or anticipated fluctuations in our financial condition and operating results;•actual or anticipated changes in our growth rate relative to our competitors;•competition from existing products or new products that may emerge;•development of new technologies that may address our markets and may make our technology less attractive;•changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;•announcements by us, our partners or our competitors of significant acquisitions, strategic partnerships, joint ventures,
following:•our status as a development-stage company and our expectation to incur losses in the future;•our ability to obtain marketing authorization from the FDA or regulatory clearance for our product candidates in the